Leonardo Flenghi

3.9k total citations
36 papers, 2.7k citations indexed

About

Leonardo Flenghi is a scholar working on Pathology and Forensic Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Leonardo Flenghi has authored 36 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 16 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Leonardo Flenghi's work include Lymphoma Diagnosis and Treatment (21 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Toxin Mechanisms and Immunotoxins (6 papers). Leonardo Flenghi is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Toxin Mechanisms and Immunotoxins (6 papers). Leonardo Flenghi collaborates with scholars based in Italy, Germany and Denmark. Leonardo Flenghi's co-authors include Brunangelo Falini, Stefano Pileri, Pier Giuseppe Pelicci, Horst Dürkop, Maria Paola Martelli, Fiorenzo Stirpe, MF Martelli, Barbara Bigerna, Roberta Pacini and M Fagioli and has published in prestigious journals such as The Lancet, Blood and The Journal of Immunology.

In The Last Decade

Leonardo Flenghi

35 papers receiving 2.7k citations

Peers

Countries citing papers authored by Leonardo Flenghi

Since Specialization

Citations

This map shows the geographic impact of Leonardo Flenghi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonardo Flenghi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonardo Flenghi more than expected).

Fields of papers citing papers by Leonardo Flenghi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonardo Flenghi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonardo Flenghi. The network helps show where Leonardo Flenghi may publish in the future.

Co-authorship network of co-authors of Leonardo Flenghi

This figure shows the co-authorship network connecting the top 25 collaborators of Leonardo Flenghi. A scholar is included among the top collaborators of Leonardo Flenghi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonardo Flenghi. Leonardo Flenghi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Case Report: Subtotal Lymphoid and Total Marrow Irradiation as Bridge Therapy to CD19-Directed CAR T Cells in a Chemorefractory DLBCL With Leukemic Involvement 2022 ·Frontiers in Immunology ·Simonetta Saldi, Vincenzo Maria Perriello, (unknown), Loredana Ruggeri, (unknown), (unknown), (unknown), (unknown), (unknown), Leonardo Flenghi, Antonio Pierini, Cynthia Aristei, Brunangelo Falini	2
2	Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas 2022 ·Cancer Management and Research ·(unknown), Alessia Castellino, (unknown), Leonardo Flenghi, (unknown), Adalberto Ibatici, Cesare Massone, Alessandro Pileri, Ilaria Proietti, (unknown), Pietro Quaglino, Serena Rupoli, Pier Luigi Zinzani	6
3	The use of indocyanine green to detect sentinel nodes in breast cancer: A prospective study 2014 ·European Journal of Surgical Oncology ·(unknown), (unknown), Ilaria Panzini, (unknown), (unknown), M. Ricci, Elisabetta Fabbri, (unknown), Leonardo Flenghi, Emiliano Tamburini, Davide Tassinari, Lorenzo Gianni	62
4	Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies Treated with Chemotherapy 2009 ·Infection ·Daniela Francisci, (unknown), Elisabetta Schiaroli, Monia Capponi, Barbara Belfiori, Leonardo Flenghi, Franco Baldelli	47
5	Vaccine Therapy of B Cell Malignancies: Different Strategies for a Novel Approach 2001 ·Leukemia & lymphoma ·Arcangelo Liso, Roberta Benedetti, Leonardo Flenghi, Brunangelo Falini	3
6	ALK Expression Defines a Distinct Group of T/Null Lymphomas (“ALK Lymphomas”) with a Wide Morphological Spectrum 1998 ·American Journal Of Pathology ·Brunangelo Falini, Barbara Bigerna, Marco Fizzotti, Karen Pulford, (unknown), Georges Delsol, Antonino Carbone, Marco Paulli, Umberto Magrini, Fabio Menestrina, Roberto Giardini, Silvana Pilotti, Alessandra Mezzelani, (unknown), Monia Billi, Alessandra Pucciarini, Roberta Pacini, Pier Giuseppe Pelicci, Leonardo Flenghi	214
7	CD30⁺ anaplastic large‐cell lymphoma, null type, with signet‐ring appearance 1997 ·Histopathology ·Brunangelo Falini, Arcangelo Liso, Laura Pasqualucci, Leonardo Flenghi, Stefano Ascani, Stefano Pileri, E Bucciarelli	32
8	Anti‐CD30 (BER‐H2) immunotoxins containing the type‐1 ribosome‐inactivating proteins momordin and PAP‐S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30⁺ tumour cells in vitro and in SCID mice 1996 ·British Journal of Haematology ·Adelmo Terenzi, Andrea Bolognesi, Laura Pasqualucci, Leonardo Flenghi, (unknown), Harald Stein, Marshall E. Kadin, Barbara Bigerna, Letizia Polito, Pier Luigi Tazzari, Maria Paola Martelli, Fiorenzo Stirpe, Brunangelo Falini	40
9	Immunotoxin therapy of hematological malignancies. 1996 ·PubMed ·Laura Pasqualucci, Leonardo Flenghi, Adelmo Terenzi, Andrea Bolognesi, Fiorenzo Stirpe, Barbara Bigerna, Brunangelo Falini	19
10	Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia 1995 ·Blood ·Leonardo Flenghi, M Fagioli, Lorenzo Tomassoni, Stefano Pileri, Marcello Gambacorta, Roberta Pacini, F Grignani, (unknown), Pier Francesco Ferrucci, MF Martelli, Pier Giuseppe Pelicci, Brunangelo Falini	96
11	PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. 1993 ·PubMed ·Brunangelo Falini, Leonardo Flenghi, Stefano Pileri, Marcello Gambacorta, Barbara Bigerna, Horst Dürkop, Florian Eitelbach, J. Thiele, Roberta Pacini, Antonio Cavaliere	257
12	Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation 1992 ·British Journal of Haematology ·Pier Luigi Tazzari, Andrea Bolognesi, Daniela de Totero, Brunangelo Falini, Roberto M. Lemoli, Marco R. Soria, (unknown), Marco Gobbi, Harald Stein, Leonardo Flenghi, Maria Paola Martelli, Fiorenzo Stirpe	70
13	Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin 1992 ·The Lancet ·Brunangelo Falini, Leonardo Flenghi, Franco Aversa, Giuliana Barbabietola, MF Martelli, (unknown), Pier Luigi Tazzari, (unknown), H. Stein, Horst Dürkop, Giovanni Pizzolo, Andrea Bolognesi, Fiorenzo Stirpe, Elena Sabattini, Stefano Pileri	171
14	In vivo targeting of Hodgkin's and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2. Immunoscintigrafic and immunohistological evidence. 1992 ·Brunangelo Falini, Leonardo Flenghi, L. Fedeli, (unknown), (unknown), H. Stein, Barbara Bigerna, Giuliana Barbabietola, S. Venturi, Giovanni Pizzolo, Andréa Bartoli, S. Pileri, Elena Sabattini, Rosanna Palumbo, MF Martelli	1
15	Expression of the intestinal T‐lymphocyte associated molecule HML‐1: analysis of 75 non‐Hodgkin's lymphomas and description of the first HML‐1 positive T‐lymphoblastic tumour 1991 ·Histopathology ·Brunangelo Falini, Leonardo Flenghi, M Fagioli, Pier Giuseppe Pelicci, H. Stein, Barbara Bigerna, Stefano Pileri, Maria Paola Martelli	13
16	LF61: a new monoclonal antibody directed against a trimeric molecule (150 kDa, 125 kDa, 105 kDa) associated with hairy cell leukaemia 1990 ·British Journal of Haematology ·Leonardo Flenghi, Fabrizio Spinozzi, H. Stein, (unknown), (unknown), Brunangelo Falini	15
17	Evolutionary conservation in various mammalian species of the human proliferation-associated epitope recognized by the Ki-67 monoclonal antibody. 1989 ·Journal of Histochemistry & Cytochemistry ·Brunangelo Falini, Leonardo Flenghi, M Fagioli, H. Stein, Roland Schwarting, Carlo Riccardi, (unknown), Stefano Pileri, Pier Giuseppe Pelicci, Luisa Lanfrancone	52
18	Distribution of T cells bearing different forms of the T cell receptor gamma/delta in normal and pathological human tissues. 1989 ·The Journal of Immunology ·Brunangelo Falini, Leonardo Flenghi, Stefano Pileri, Pier Giuseppe Pelicci, M Fagioli, Maria Paola Martelli, Lorenzo Moretta, Ermanno Ciccone	185
19	Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki‐67 and anti‐bromo‐deoxyuridine monoclonal antibodies 1988 ·British Journal of Haematology ·Brunangelo Falini, (unknown), Stefano Sacchi, (unknown), Maria Paola Martelli, Johannes Gerdes, H. Stein, Stefano Pileri, Marco Gobbi, M Fagioli, Olivia Minelli, Leonardo Flenghi	40
20	Expression of lymphoid‐associated antigens on Hodgkin's and Reed‐Sternberg cells of Hodgkin's disease. An immunocytochemical study on lymph node cytospins using monoclonal antibodies 1987 ·Histopathology ·Brunangelo Falini, H. Stein, Stefano Pileri, (unknown), (unknown), Maria Paola Martelli, F Grignani, M Fagioli, Olivia Minelli, (unknown), Leonardo Flenghi	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact